Efficacy and safety of an intraoral electrostimulation device for xerostomia relief: a multicenter, randomized trial
To evaluate the efficacy and safety of an intraoral electrostimulation device, consisting of stimulating electrodes, an electronic circuit, and a power source, in treating xerostomia. The device delivers electrostimulation through the oral mucosa to the lingual nerve in order to enhance the salivary...
- Autores:
-
Strietzel, Frank P
Lafaurie, Gloria Ines
Bautista Mendoza, Gloria R.
Alajbeg, Ivan
Pejda, Slavica
Vuletić, Lea
Mantilla, Rubén
Falcão, Denise P.
Leal, Soraya C.
Barreto Bezerra, Ana C.
Tran, Simon D.
Ménard, Henri A.
Kimoto, Suguru
Pan, Shaoxia
Martín-Granizo, Rafael A.
Maniegas Lozano, M. Lourdes
Zunt, Susan L.
Krushinski, Cheryl A.
Melilli, Dario
Campisi, Giuseppina
Paderni, Carlo
Dolce, Sonia
Yepes, Juan F.
Lindh, Liselott
Koray, Meltem
Mumcu, Gonca
Elad, Sharon
Zeevi, Itai
Aldape Barrios, Beatriz C.
López Sánchez, Rodrigo M.
Beiski, Ben Z.
Wolff, Andy
Konttinen, Yrjö T.
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2011
- Institución:
- Universidad El Bosque
- Repositorio:
- Repositorio U. El Bosque
- Idioma:
- eng
- OAI Identifier:
- oai:repositorio.unbosque.edu.co:20.500.12495/5230
- Acceso en línea:
- http://hdl.handle.net/20.500.12495/5230
https://doi.org/10.1002/art.27766
https://repositorio.unbosque.edu.co
- Palabra clave:
- Oral cavity
Toxicity
Rheumatology
- Rights
- openAccess
- License
- Acceso abierto
Summary: | To evaluate the efficacy and safety of an intraoral electrostimulation device, consisting of stimulating electrodes, an electronic circuit, and a power source, in treating xerostomia. The device delivers electrostimulation through the oral mucosa to the lingual nerve in order to enhance the salivary reflex. The device was tested on a sample of patients with xerostomia due to Sjögren's syndrome and other sicca conditions in a 2-stage prospective, randomized, multicenter trial. Stage I was a double-blind, crossover stage designed to compare the effects of the electrically active device with the sham device, each used for 1 month, and stage II was a 3-month open-label stage designed to assess the long-term effects of the active device. Improvement in xerostomia severity from baseline was the primary outcome measure. A total of 114 patients were randomized. In stage I, the active device performed better than the sham device for patient-reported xerostomia severity (P<0.002), xerostomia frequency (P<0.05), quality of life impairment (P<0.01), and swallowing difficulty (P<0.02). At the end of stage II, statistically significant improvements were verified for patient-reported xerostomia severity (P<0.0001), xerostomia frequency (P<0.0001), oral discomfort (P<0.001), speech difficulty (P<0.02), sleeping difficulty (P<0.001), and resting salivary flow rate (P<0.01). Our findings indicate that daily use of the device alleviated oral dryness, discomfort, and some complications of xerostomia, such as speech and sleeping difficulties, and increased salivary output. The results show a cumulative positive effect of the device over the period of the study, from baseline to the end of the trial. |
---|